Global Immunotherapy Drugs Market to Reach $201 Billion by 2021: Increasing Adoption of Targeted Therapies …Yahoo FinanceThe global immunotherapy drugs market is projected to reach USD 201.52 Billion by 2021 from USD 108.41 Billion in 2016, growing a… Continue reading
Medical News TodayDiabetes: Stimulating bone stem cells may improve fracture repairMedical News TodayIn further experiments, they discovered a protein that stimulates the bone stem cells. When they applied the protein to bone fracture sites in the mice… Continue reading
OncLiveEfforts Continue to Expand Immunotherapy Impact in SarcomaOncLiveAre there any new data with these immunotherapy agents that are being presented here at CTOS? There have been a number of different abstracts presented that were very interesting, … Continue reading
Global Immunotherapy Drugs Market to Reach $201 Billion by 2021: Increasing Adoption of Targeted Therapies …Satellite PR News (press release)The global immunotherapy drugs market is projected to reach USD 201.52 Billion by 2021 from USD 108.41 Billio… Continue reading
San Francisco Business Times |
Gene therapy’s big surprise may be in an old South S.F. warehouse
San Francisco Business Times In our latest BioFlash podcast from the 35th annual J.P. Morgan Healthcare Conference, Audentes CEO Matt Patterson talks about the three gene therapies that the San Francisco-based company expects to take into clinical trials this year and the company … |
Seeking Alpha |
RXi Pharmaceuticals Acquires MirImmune For Cancer Immunotherapy Prospects
Seeking Alpha The deal brings two drug candidates and the potential to market RXi’s platform to the significant cancer immunotherapy market. I’m positive on RXII’s short- and medium-term prospects. Quick Take. Dermal scarring treatment company RXi Pharmaceuticals … |
|
MaxCyte, NIH NIAID Study Published in Science Translational Medicine Demonstrates CRISPR-Cas9 Repair of X …
PR Newswire (press release) The study was published in Science Translational Medicinei and entitled “CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease.” Using MaxCyte’s patented Flow Electroporation™ Technology, … |